Anil Okay

Anil Okay is an entrepreneur and the founder and CEO of Adalvo, one of the fastest-growing global B2B pharmaceutical companies. Since launching the company in 2018, he has built Adalvo from the ground up into a top three player worldwide. Under his leadership, Adalvo has delivered exceptional results, with EBITDA doubling every single year since inception. Today, the company holds the industry’s largest B2B pharma pipeline and continues its impressive growth trajectory, powered by an agile and innovative business model.

With nearly two decades of experience in the pharmaceutical sector, Anil is a proven P&L leader and commercial strategist with deep expertise in M&A, licensing, deal-making, and building sustainable partnerships. Over his career, he has executed transactions exceeding $25 billion, consistently driving growth, turnarounds, and value creation.

Before he launched Adalvo, Anil was a founding member of Alvotech's management team, serving as Chief Commercial Officer until October 2025. He built the company's go-to-market model, secured multi-billion-dollar partnerships, and was pivotal in its IPO and triple Nasdaq listings in the US, Sweden, and Iceland. Earlier, he led Global Sales and Licensing at HELM AG, and held senior commercial roles at Abdi Ibrahim, managing operations across 40+ markets. He began his career at Sanofi, progressing from medical sales into business development.

Anil holds a Bachelor of Engineering in Mathematics & Computer Engineering and Business Administration (with honors) from Vienna Technical University and Istanbul Kultur University, as well as a Master’s in Marketing Management from Galatasaray University. He has further enhanced his leadership skills through executive education at Harvard and INSEAD.

He was recognized as “Leader of the Year” at the 2021 Global Generics and Biosimilars Awards and has received multiple other industry accolades.